Welcome to our dedicated page for Medicenna Therapeutics SEC filings (Ticker: MDNAF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Medicenna Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Medicenna Therapeutics's regulatory disclosures and financial reporting.
Medicenna Therapeutics Corp., a Canadian biotechnology company, is conducting a U.S. private offering of units under Rule 506(b) of Regulation D. Each unit consists of one common share and one-half of a common share purchase warrant; each whole warrant allows purchase of one share at an exercise price of C$0.65 for three years following May 28, 2026.
The company reports $253,458 USD in securities sold, with an additional $2,089,942 USD potentially payable to Medicenna if U.S. investors exercise the warrants. No finders' fees are being paid, and proceeds may be used in the ordinary course, including salaries for certain executive officers and directors.